UCB: FDA panel approves osteoporosis drug
(CercleFinance.com) - An advisory panel has recommended that US health regulators approve the use of UCB and Amgen's Evenity drug for the treatment of postmenopausal women with osteoporosis at high risk of fracture.
The Food and Drug Administration's advisers voted 18-to-1 in favour of the drug's approval after reviewing safety and efficacy data from Phase 3 studies.
However, the committee emphasized the need for a post-marketing follow-up. Belgium-listed UCB shares are currently down 0.2% after this news.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Food and Drug Administration's advisers voted 18-to-1 in favour of the drug's approval after reviewing safety and efficacy data from Phase 3 studies.
However, the committee emphasized the need for a post-marketing follow-up. Belgium-listed UCB shares are currently down 0.2% after this news.
Copyright (c) 2019 CercleFinance.com. All rights reserved.